Browsing Tag
J.P. Morgan
39 posts
Did Tango Therapeutics Inc. just turn one cancer data shock into a $600m runway?
Find out how Tango Therapeutics Inc.'s $600 million offering could reshape TNGX sentiment, dilution risk, and its oncology runway.
Quantinuum IPO closes at $1.68bn, but QNT trading shows investors want proof beyond quantum hype
Quantinuum raised $1.68bn, but QNT’s early trading asks the real question: can quantum computing turn promise into revenue?
Tega Industries completes $1.5bn Molycop acquisition with Apollo Funds as TEGA scales global mining consumables platform
Tega now controls Molycop, but the USD 1.5bn deal’s real test is integration. Read how TEGA could reshape mining consumables.
Delivery Hero (DHER) stock up 4% to €29.5 as Aspex forces CEO exit and Korea sale opens
Aspex pushed out the CEO and bought 5% more. Prosus must keep selling. Korea is on the block. Delivery Hero (XETRA: DHER) is being rebuilt in real time.
Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market
Angelini Pharma will pay $4.1 billion for Catalyst Pharmaceuticals at $31.50 a share, but CPRX closed at $31.10. The premium sits in the strategy, not the price.
Kaoko Metals (KAO) lists on ASX with A$6.5m IPO and a Namibian copper portfolio chasing a structurally short market
LME copper sits near record highs. Junior raises keep failing. Kaoko Metals just cleared an oversubscribed A$6.5m IPO. Chalkos drilling decides the rest.
Pharma M&A trends 2026: Why $1.3tn in firepower is meeting the steepest patent cliff in industry history
Big pharma has $1.3 trillion to deploy and $230 billion in revenue going off-patent by 2030. The 2026 deal map shows where the panic is real.
Seaport Therapeutics seeks $212m IPO as neuropsychiatry biotech window reopens
Seaport’s IPO tests biotech appetite before key depression data. Here’s why SPTX, PureTech, and psychiatry investors are watching.
Hut 8 (NASDAQ: HUT) stock faces AI infrastructure test as $3.25bn notes plan funds River Bend data center
Hut 8 wants AI infrastructure scale without equity dilution. Its $3.25B debt plan now tests whether River Bend can deliver.
WBD stock sits near $27 as $31 Paramount offer clears shareholder vote: Inside the merger arb gap and regulatory risk
WBD shareholders approve $110bn Paramount Skydance takeover. What the deal means for Hollywood, media consolidation, and the regulatory road ahead.